Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in rats with cavernous transformation of portal vein and their role in peripheral angiogenesis

doi:10.3969/j.issn.2095-4344.2015.18.017

Abstract

Abstract:

BACKGROUND: At present, there is no effective treatment strategy for cavernous transformation of portal vein and basic research about its etiology is rarely reported.
OBJECTIVE: To establish the models of cavernous transformation of portal vein, detect the expression of matrix metalloproteinase-2, -9 (MMP-2, MMP-9) and tissue inhibitors 1, 2 of metalloproteinase (TIMP-1, TIMP-2) in rat portal vein and peripheral tissue, and discuss the roles in the process of peripheral angiogenesis.
METHODS: Eighty Sprague-Dawley rats were randomly divided into three groups. The rat models of cavernous
transformation of portal vein were established with partial coarctation in portal vein by using 21 G blunt pinhead. Control group was normal rats without operation (samples were harvested after portal vein radiography). Model group and sham operation group were divided into three groups respectively according to different time points, namely 2, 4 and 6 weeks after operation. Rats of each group were randomly chosen at week 2, 4 and 6 after operation to observe the formation of collateral circulation of portal vein and its peripheral tissues by performing portal vein radiography. CD31 was detected by immunohistochemistry. The expression of MMP-2, MMP-9, TIMP-1, TIMP-2 mRNA and protein in portal vein and peripheral tissue were determined by RT-PCR and immunohistochemistry respectively.
RESULTS AND CONCLUSION: Peripheral angiogenesis of model group was increased obviously by portal vein radiography and immunohistochemistry. RT-PCR and immunohistochemistry results demonstrated that, compared with the control group and sham operation group, the expression of MMP-2 mRNA and protein in model group were significantly increased at weeks 2, 4, and 6 (P < 0.01, P < 0.05), while expression of MMP-9 mRNA and protein at week 2 in model group were significantly higher than that in the control group and sham operation group. Expression of TIMP-1 and TIMP-2 in model group showed no significant difference compared with control group and sham operation group at weeks 2, 4, and 6 (P > 0.05). Ratio of MMP-2/TIMP-2 of model group was significantly higher than that of control group and sham operation group (P < 0.05) at week 2. the rat models of cavernous transformation of portal vein have low mortality, high success rate and are stable. Upregulation of the expression of MMP-2, MMP-9 and the disbanlance of the ratio of MMP-2/TIMP-2 might contribute to the peripheral angiogenesis in rats with cavernous transformation of portal vein.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: Portal Vein, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9

CLC Number:

R318

Zhao Lu, Liu Lei, Mao Jian-xiong, Wang Jian-yao, Xu Jin-yong, Ye Xiao-shuo. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in rats with cavernous transformation of portal vein and their role in peripheral angiogenesis[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(18): 2884-2890.

Figures/Tables 2

References

[1] Gibson JR.Cavernous transformation of the portal vein.J Pathol Bact.1955;70:81-95.
[2] De Gaetano AM,Lafortune M,Patriquin H,et al.Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. AJR Am J Roentgenol.1995;165:1151-1155.
[3] Fernandez M, Mejias M, Angermayr B,et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.Hepatol.2005;43 (1):98-103.
[4] 梁颖,蒋涛,王亚杰,等. 螺旋CT评价门静脉海绵样变性及其侧支循环的特点[J].中国医学影像技术,2008,24(7):1076-1079.
[5] Hijova E. Matrix metalloproteinases:their biological funcations and clinical implications.Bratisl Lek Listy.2005;106(3): 127-132.
[6] Chistiakov DA,Sobenin IA,Orekhov AN.Vascular extracellular matrix in atherosclerosis. Cardiol Rev.2013;21(6):270-288.
[7] 王建尧,刘磊,王斌,等.门静脉海绵样变性大鼠模型制作方法的探讨及体会[J].中国普外基础与临床杂志,2010,17(1):46-51.
[8] 毛建雄,刘磊,王斌,等.门静脉部分缩窄制作SD大鼠门静脉海绵样变性动物模型[J].中国优生与遗传杂志,2012,20(6):89-91.
[9] Fernandez M, Mejias M, Garcia-Pras E,et al. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology. 2007;46(4):1208-1217.
[10] Mejias M, Garcia-Pras E, Tiani C,et al. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. Cell Mol Med. 2008;12(5A):1690-1699.
[11] Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogemc phenotype in anlulor model.Proc Natl Acad Sci U S A. 2000;97(8):3884-3889.
[12] 王兆京,张丹丹,陈志伟,等.MMP-9与VEGF在成人肝血管瘤中的表达及其意义[J].东南大学学报,2014,33(1):66-70.
[13] Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol.2011;12(11):233.
[14] Rosenberg GA , Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke.1998;29(10):2189-2195.
[15] van Hinsbergh VW, Engelse MA, Quax PH. Pericellular protcases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26(4):716-728.
[16] 刘海龙,吴黎明,许圆圆. 在体大鼠心肌缺血再灌注中MMP-2/9、TIMP-1 /2mRNA和蛋白表达及MMP-2/9酶活性的同步动态变化[J]. 中国分子心脏病学杂志,2009.9(6):332-337.
[17] Lu H, Cao X, Zhang H,et al. Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways. Tumour Biol, 2014.2. [Epub ahead of print].
[18] Mohamed MM, EI-Ghonaimy EA, Nouh MA, et al. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol. 2014; 46:138-147.
[19] Marzano AV, Cugno M, Trevisan V, et al. Inflammatory cells, cytokines and matrix metalloproteinases in amicrobial pustulosis of the folds and other neutrophilic dermatoses. Int J Immunopathol Pharmacol. 2011;24(2):451-460.
[20] Nagase H1, Woessner JF Jr. Matrix Metalloproteinases. J Biol Chem. 1999;274(31):21491-21494..
[21] Dimas G, Iliadis F, Grekas D. Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: Linkage-based approaches. Hippokratia. 2013;17(4):292-297